Cocrystal Applications in Drug Delivery

doi:10.3390/books978-3-03943-984-3

Download Url(s)

https://mdpi.com/books/pdfview/book/3399

Contributor(s)

Erxleben, Andrea (editor)

Language

English

Show full item record

Abstract

In 2015, the first pharmaceutical cocrystal was approved by the FDA. Since then, the number of cocrystals on the market and in the development pipeline has been slowly but steadily growing. It is now well established that cocrystals are a versatile new approach to oral drug formulation. This Reprint Book is a collection of articles that show the utility of pharmaceutical cocrystals and various aspects of cocrystal research: • Cocrystals as a strategy to modify the physicochemical properties of a drug such as dissolution behaviour, tabletability, and melting point; • Development of new coformers; • Screening studies for multiple cocrystal forms; • Cocrystals in nano-sized drug delivery.

URI

https://directory.doabooks.org/handle/20.500.12854/68386

Keywords

nitazoxanide; cocrystals; multicomponent crystals; dissolution behavior; supersaturated formulations; crystallization inhibitors; drug-polymer interactions; nano co-crystals; crystal engineering; polydispersity index; zeta potential; particle size; zidovudine; lamivudine; HIV/AIDS; sonochemistry; imidazole N-oxides; barbituric acid; thiobarbituric acid; pharmaceutical cocrystals; mechanochemistry; solid state NMR; X-ray Diffraction; design of experiments; Quality by Design; cocrystal; compaction; nanoindentation; slip plane; tabletability; surface topology; interparticulate bonding area; interparticulate bonding strength; nefiracetam; solid state; solubility; dissolution rate; stability; formulation; diclofenac sodium; L-proline; salt cocrystal; multicomponent crystal; monohydrate; tetrahydrate; dissolution; itraconazole; terephthalic acid; crystal structure; solid-state; thermal analysis; wettability; n/a